1
|
Vidal B, Zimmer L. Editorial: In vivo functional neuroimaging for pharmacology. Front Neurosci 2023; 17:1279587. [PMID: 37811330 PMCID: PMC10552635 DOI: 10.3389/fnins.2023.1279587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Accepted: 09/07/2023] [Indexed: 10/10/2023] Open
|
2
|
Chaib S, Vidal B, Bouillot C, Depoortere R, Newman-Tancredi A, Zimmer L, Levigoureux E. Multimodal imaging study of the 5-HT 1A receptor biased agonist, NLX-112, in a model of L-DOPA-induced dyskinesia. Neuroimage Clin 2023; 39:103497. [PMID: 37632990 PMCID: PMC10474496 DOI: 10.1016/j.nicl.2023.103497] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Revised: 07/20/2023] [Accepted: 08/14/2023] [Indexed: 08/28/2023]
Abstract
INTRODUCTION The leading treatment for motor signs of Parkinson's disease is L-DOPA, but, upon extended use, it can lead to levodopa-induced dyskinesia (LID). Serotonergic neurons are involved in LID etiology and previous pre-clinical studies have shown that NLX-112, a 5-HT1A biased agonist, has robust antidyskinetic effects. Here, we investigated its effects in hemiparkinsonian (HPK) rats with a unilateral nigrostriatal 6-OHDA lesion. METHODS We compared HPK rats with LID (i.e., sensitized to the dyskinetic effects of chronic L-DOPA) and without LID (HPK-non-LID), using [18F]FDG PET imaging and fMRI functional connectivity following systemic treatment with saline, L-DOPA, NLX-112 or L-DOPA + NLX-112. RESULTS In HPK-non-LID rats, [18F]FDG PET experiments showed that L-DOPA led to hypermetabolism in motor areas (cerebellum, brainstem, and mesencephalic locomotor region) and to hypometabolism in cortical regions. L-DOPA effects were also observed in HPK-LID rats, with the additional emergence of hypermetabolism in raphe nuclei and hypometabolism in hippocampus and striatum. NLX-112 attenuated L-DOPA-induced raphe hypermetabolism and cingulate cortex hypometabolism in HPK-LID rats. Moreover, in fMRI experiments NLX-112 partially corrected the altered neural circuit connectivity profile in HPK-LID rats, through activity in regions rich in 5-HT1A receptors. CONCLUSION This neuroimaging study sheds light for the first time on the brain activation patterns of HPK-LID rats. The 5-HT1A receptor agonist, NLX-112, prevents occurrence of LID, likely by activating pre-synaptic autoreceptors in the raphe nuclei, resulting in a partial restoration of brain metabolic and connectivity profiles. In addition, NLX-112 also rescues L-DOPA-induced deficits in cortical activation, suggesting potential benefit against non-motor symptoms of Parkinson's disease.
Collapse
|
3
|
Chaib S, Bouillot C, Bouvard S, Vidal B, Zimmer L, Levigoureux E. Single subanesthetic dose of ketamine produces delayed impact on brain [ 18F]FDG PET imaging and metabolic connectivity in rats. Front Neurosci 2023; 17:1213941. [PMID: 37521685 PMCID: PMC10372660 DOI: 10.3389/fnins.2023.1213941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 06/23/2023] [Indexed: 08/01/2023] Open
Abstract
Introduction Ketamine, a glutamate NMDA receptor antagonist, is suggested to act very rapidly and durably on the depressive symptoms including treatment-resistant patients but its mechanisms of action remain unclear. There is a requirement for non-invasive biomarkers, such as imaging techniques, which hold promise in monitoring and elucidating its therapeutic impact. Methods We explored the glucose metabolism with [18F]FDG positron emission tomography (PET) in ten male rats in a longitudinal study designed to compare imaging patterns immediately after acute subanaesthetic ketamine injection (i.p. 10 mg/kg) with its sustained effects, 5 days later. Changes in [18F]FDG uptake following ketamine administration were estimated using a voxel-based analysis with SPM12 software, and a region of interest (ROI) analysis. A metabolic connectivity analysis was also conducted to estimate the immediate and delayed effects of ketamine on the inter-individual metabolic covariance between the ROIs. Results No significant difference was observed in brain glucose metabolism immediately following acute subanaesthetic ketamine injection. However, a significant decrease of glucose uptake appeared 5 days later, reflecting a sustained and delayed effect of ketamine in the frontal and the cingulate cortex. An increase in the raphe, caudate and cerebellum was also measured. Moreover, metabolic connectivity analyses revealed a significant decrease between the hippocampus and the thalamus at day 5 compared to the baseline. Discussion This study showed that the differences in metabolic profiles appeared belatedly, 5 days after ketamine administration, particularly in the cortical regions. Finally, this methodology will help to characterize the effects of future molecules for the treatment of treatment resistant depression.
Collapse
|
4
|
Grandjean J, Desrosiers-Gregoire G, Anckaerts C, Angeles-Valdez D, Ayad F, Barrière DA, Blockx I, Bortel A, Broadwater M, Cardoso BM, Célestine M, Chavez-Negrete JE, Choi S, Christiaen E, Clavijo P, Colon-Perez L, Cramer S, Daniele T, Dempsey E, Diao Y, Doelemeyer A, Dopfel D, Dvořáková L, Falfán-Melgoza C, Fernandes FF, Fowler CF, Fuentes-Ibañez A, Garin CM, Gelderman E, Golden CEM, Guo CCG, Henckens MJAG, Hennessy LA, Herman P, Hofwijks N, Horien C, Ionescu TM, Jones J, Kaesser J, Kim E, Lambers H, Lazari A, Lee SH, Lillywhite A, Liu Y, Liu YY, López-Castro A, López-Gil X, Ma Z, MacNicol E, Madularu D, Mandino F, Marciano S, McAuslan MJ, McCunn P, McIntosh A, Meng X, Meyer-Baese L, Missault S, Moro F, Naessens DMP, Nava-Gomez LJ, Nonaka H, Ortiz JJ, Paasonen J, Peeters LM, Pereira M, Perez PD, Pompilus M, Prior M, Rakhmatullin R, Reimann HM, Reinwald J, Del Rio RT, Rivera-Olvera A, Ruiz-Pérez D, Russo G, Rutten TJ, Ryoke R, Sack M, Salvan P, Sanganahalli BG, Schroeter A, Seewoo BJ, Selingue E, Seuwen A, Shi B, Sirmpilatze N, Smith JAB, Smith C, Sobczak F, Stenroos PJ, Straathof M, Strobelt S, Sumiyoshi A, Takahashi K, Torres-García ME, Tudela R, van den Berg M, van der Marel K, van Hout ATB, Vertullo R, Vidal B, Vrooman RM, Wang VX, Wank I, Watson DJG, Yin T, Zhang Y, Zurbruegg S, Achard S, Alcauter S, Auer DP, Barbier EL, Baudewig J, Beckmann CF, Beckmann N, Becq GJPC, Blezer ELA, Bolbos R, Boretius S, Bouvard S, Budinger E, Buxbaum JD, Cash D, Chapman V, Chuang KH, Ciobanu L, Coolen BF, Dalley JW, Dhenain M, Dijkhuizen RM, Esteban O, Faber C, Febo M, Feindel KW, Forloni G, Fouquet J, Garza-Villarreal EA, Gass N, Glennon JC, Gozzi A, Gröhn O, Harkin A, Heerschap A, Helluy X, Herfert K, Heuser A, Homberg JR, Houwing DJ, Hyder F, Ielacqua GD, Jelescu IO, Johansen-Berg H, Kaneko G, Kawashima R, Keilholz SD, Keliris GA, Kelly C, Kerskens C, Khokhar JY, Kind PC, Langlois JB, Lerch JP, López-Hidalgo MA, Manahan-Vaughan D, Marchand F, Mars RB, Marsella G, Micotti E, Muñoz-Moreno E, Near J, Niendorf T, Otte WM, Pais-Roldán P, Pan WJ, Prado-Alcalá RA, Quirarte GL, Rodger J, Rosenow T, Sampaio-Baptista C, Sartorius A, Sawiak SJ, Scheenen TWJ, Shemesh N, Shih YYI, Shmuel A, Soria G, Stoop R, Thompson GJ, Till SM, Todd N, Van Der Linden A, van der Toorn A, van Tilborg GAF, Vanhove C, Veltien A, Verhoye M, Wachsmuth L, Weber-Fahr W, Wenk P, Yu X, Zerbi V, Zhang N, Zhang BB, Zimmer L, Devenyi GA, Chakravarty MM, Hess A. Author Correction: A consensus protocol for functional connectivity analysis in the rat brain. Nat Neurosci 2023:10.1038/s41593-023-01328-1. [PMID: 37072562 DOI: 10.1038/s41593-023-01328-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
|
5
|
Grandjean J, Desrosiers-Gregoire G, Anckaerts C, Angeles-Valdez D, Ayad F, Barrière DA, Blockx I, Bortel A, Broadwater M, Cardoso BM, Célestine M, Chavez-Negrete JE, Choi S, Christiaen E, Clavijo P, Colon-Perez L, Cramer S, Daniele T, Dempsey E, Diao Y, Doelemeyer A, Dopfel D, Dvořáková L, Falfán-Melgoza C, Fernandes FF, Fowler CF, Fuentes-Ibañez A, Garin CM, Gelderman E, Golden CEM, Guo CCG, Henckens MJAG, Hennessy LA, Herman P, Hofwijks N, Horien C, Ionescu TM, Jones J, Kaesser J, Kim E, Lambers H, Lazari A, Lee SH, Lillywhite A, Liu Y, Liu YY, López-Castro A, López-Gil X, Ma Z, MacNicol E, Madularu D, Mandino F, Marciano S, McAuslan MJ, McCunn P, McIntosh A, Meng X, Meyer-Baese L, Missault S, Moro F, Naessens DMP, Nava-Gomez LJ, Nonaka H, Ortiz JJ, Paasonen J, Peeters LM, Pereira M, Perez PD, Pompilus M, Prior M, Rakhmatullin R, Reimann HM, Reinwald J, Del Rio RT, Rivera-Olvera A, Ruiz-Pérez D, Russo G, Rutten TJ, Ryoke R, Sack M, Salvan P, Sanganahalli BG, Schroeter A, Seewoo BJ, Selingue E, Seuwen A, Shi B, Sirmpilatze N, Smith JAB, Smith C, Sobczak F, Stenroos PJ, Straathof M, Strobelt S, Sumiyoshi A, Takahashi K, Torres-García ME, Tudela R, van den Berg M, van der Marel K, van Hout ATB, Vertullo R, Vidal B, Vrooman RM, Wang VX, Wank I, Watson DJG, Yin T, Zhang Y, Zurbruegg S, Achard S, Alcauter S, Auer DP, Barbier EL, Baudewig J, Beckmann CF, Beckmann N, Becq GJPC, Blezer ELA, Bolbos R, Boretius S, Bouvard S, Budinger E, Buxbaum JD, Cash D, Chapman V, Chuang KH, Ciobanu L, Coolen BF, Dalley JW, Dhenain M, Dijkhuizen RM, Esteban O, Faber C, Febo M, Feindel KW, Forloni G, Fouquet J, Garza-Villarreal EA, Gass N, Glennon JC, Gozzi A, Gröhn O, Harkin A, Heerschap A, Helluy X, Herfert K, Heuser A, Homberg JR, Houwing DJ, Hyder F, Ielacqua GD, Jelescu IO, Johansen-Berg H, Kaneko G, Kawashima R, Keilholz SD, Keliris GA, Kelly C, Kerskens C, Khokhar JY, Kind PC, Langlois JB, Lerch JP, López-Hidalgo MA, Manahan-Vaughan D, Marchand F, Mars RB, Marsella G, Micotti E, Muñoz-Moreno E, Near J, Niendorf T, Otte WM, Pais-Roldán P, Pan WJ, Prado-Alcalá RA, Quirarte GL, Rodger J, Rosenow T, Sampaio-Baptista C, Sartorius A, Sawiak SJ, Scheenen TWJ, Shemesh N, Shih YYI, Shmuel A, Soria G, Stoop R, Thompson GJ, Till SM, Todd N, Van Der Linden A, van der Toorn A, van Tilborg GAF, Vanhove C, Veltien A, Verhoye M, Wachsmuth L, Weber-Fahr W, Wenk P, Yu X, Zerbi V, Zhang N, Zhang BB, Zimmer L, Devenyi GA, Chakravarty MM, Hess A. A consensus protocol for functional connectivity analysis in the rat brain. Nat Neurosci 2023; 26:673-681. [PMID: 36973511 PMCID: PMC10493189 DOI: 10.1038/s41593-023-01286-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2022] [Accepted: 02/15/2023] [Indexed: 03/29/2023]
Abstract
Task-free functional connectivity in animal models provides an experimental framework to examine connectivity phenomena under controlled conditions and allows for comparisons with data modalities collected under invasive or terminal procedures. Currently, animal acquisitions are performed with varying protocols and analyses that hamper result comparison and integration. Here we introduce StandardRat, a consensus rat functional magnetic resonance imaging acquisition protocol tested across 20 centers. To develop this protocol with optimized acquisition and processing parameters, we initially aggregated 65 functional imaging datasets acquired from rats across 46 centers. We developed a reproducible pipeline for analyzing rat data acquired with diverse protocols and determined experimental and processing parameters associated with the robust detection of functional connectivity across centers. We show that the standardized protocol enhances biologically plausible functional connectivity patterns relative to previous acquisitions. The protocol and processing pipeline described here is openly shared with the neuroimaging community to promote interoperability and cooperation toward tackling the most important challenges in neuroscience.
Collapse
|
6
|
Hernández-Meneses M, Llopis J, Sandoval E, Ninot S, Vidal B, Fernández-Pittol M, Cuervo G, Tolosana J, Moreno A, Miro J. PREVALENCIA, CARACTERÍSTICAS Y PRONÓSTICO DE LA ENDOCARDITIS SOBRE DEC CUANDO EL DISPOSITIVO NO PUEDE SER RETIRADO. CIRUGIA CARDIOVASCULAR 2023. [DOI: 10.1016/j.circv.2022.12.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
|
7
|
Fernández-Cisneros A, Hernández-Meneses M, Llopis J, Sandoval E, Pereda D, Alcocer J, Barriuso C, Castellá M, Ambrosioni J, Pericàs JM, Vidal B, Falces C, Ibáñez C, Perdomo J, Rovira I, García-de-la-María C, Moreno A, Almela M, Perisinotti A, Dahl A, Castro P, Miró JM, Quintana E. Risk scores' performance and their impact on operative decision-making in left-sided endocarditis: a cohort study. Eur J Clin Microbiol Infect Dis 2023; 42:33-42. [PMID: 36346471 PMCID: PMC9816251 DOI: 10.1007/s10096-022-04516-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Accepted: 10/20/2022] [Indexed: 11/10/2022]
Abstract
The accuracy of contemporary risk scores in predicting perioperative mortality in infective endocarditis (IE) remains controversial. The aim is to evaluate the performance of existent mortality risk scores for cardiovascular surgery in IE and the impact on operability at high-risk thresholds. A single-center retrospective review of adult patients diagnosed with acute left-sided IE undergoing surgery from May 2014 to August 2019 (n = 142) was done. Individualized risk calculation was obtained according to the available mortality risk scores: EuroScore I and II, PALSUSE, Risk-E, Costa, De Feo-Cotrufo, AEPEI, STS-risk, STS-IE, APORTEI, and ICE-PCS scores. A cross-validation analysis was performed on the score with the best area under the curve (AUC). The 30-day survival was 96.5% (95%CI 91-98%). The score with worse area under the curve (AUC = 0.6) was the STS-IE score, while the higher was for the RISK-E score (AUC = 0.89). The AUC of the majority of risk scores suggested acceptable performance; however, statistically significant differences in expected versus observed mortalities were common. The cross-validation analysis showed that a large number of survivors (> 75%) would not have been operated if arbitrary high-risk threshold estimates had been used to deny surgery. The observed mortality in our cohort is significantly lower than is predicted by contemporary risk scores. Despite the reasonable numeric performance of the analyzed scores, their utility in judging the operability of a given patient remains questionable, as demonstrated in the cross-validation analysis. Future guidelines may advise that denial of surgery should only follow a highly experienced Endocarditis Team evaluation.
Collapse
|
8
|
Amoura Z, Jousse Joulin S, Mathian A, Bonnotte B, Girard C, Le Guern V, Thabut G, Todea R, Vidal B, Lahouegue A, Suau D, Fabry-Vendrand C, Chasset F. Premières données d’utilisation d’anifrolumab en France chez les patients atteints d’un lupus érythémateux systémique. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
9
|
Vidal B, Pereira M, Valdebenito M, Vidal L, Mouthon F, Zimmer L, Charvériat M, Droguerre M. Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model. J Psychopharmacol 2022; 36:1273-1279. [PMID: 36205074 DOI: 10.1177/02698811221128963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND There is an urgent need to understand and reverse cognitive impairment. The lack of appropriate animal models combined with the limited knowledge of pathophysiological mechanisms makes the development of new cognition-enhancing drugs complex. Scopolamine is a pharmacologic agent which impairs cognition and functional imaging in a wide range of animal species, similarly to what is seen in cognitive impairment in humans. METHODS In this study, using a functional ultrasound (fUS) neuroimaging technique, we monitored the impact of donepezil (DPZ), a potent acetylcholinesterase inhibitor and first-line treatment in patients with mild to moderate Alzheimer's disease, in a scopolamine-induced mouse model. RESULTS We demonstrated that despite its low impact on the cerebral blood volume (CBV) signal, scopolamine injection produced an overall decrease in functional connectivity between various brain areas. In addition, we revealed that DPZ induced a strong decrease in CBV signal without causing a difference in functional connectivity. CONCLUSION Finally, our work highlighted that DPZ counteracted the impact of scopolamine on functional connectivity changes and confirmed the interest of using pharmaco-fUS imaging on cognitive disorders, both in frequent and rare neurological disorders.
Collapse
|
10
|
García-González J, García-de-la-Mària C, Cañas M, Rubio E, Hernández-Meneses M, Ambrosioni J, Vidal B, Sandoval E, Moreno A, Miró J. Actividad in vitro de Ampicilina más Ceftriaxona Frente a e. Gallynarum, e. Durans y e. Casseliflavus Aislados en Pacientes con Endocarditis. CIRUGIA CARDIOVASCULAR 2022. [DOI: 10.1016/j.circv.2022.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Calvo-Lopez M, Arranz R, Marin J, Gruosso D, Falces-Salvador C, Roque M, Andrea R, Vidal B, Sitges M, Sanz-De La Garza M. Cardiac telerrehabilitation: a safe and effective alternative in patients with coronary artery disease. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Other. Main funding source(s): Ferrer Internaciona Groupl, S.A
Background
Center-based cardiac rehabilitation programs (CRP) have shown to reduce morbidity and mortality after an ischemic cardiac event, but their vastly underutilized. Home-based CRP seems to improve patient’s adherence, but there is still scarce evidence, especially in elderly patients and women.
Purpose
To develop a holistic home-based CRP for ischemic heart disease patients and evaluate its safety and impact on functional capacity, adherence to a heart-healthy lifestyle and quality of life.
Methods
The 8-week home-based CRP will include 60 patients (50% women) with no age limit who have suffered an acute myocardial infarction in the previous 3 months, with LVEF ≥40% and a tablet/mobile device. The CRP (Picture 1) includes 3 weekly exercise sessions combining tailored aerobic and strength training and 1 weekly educational session focused on lifestyle habits, therapeutic adherence, and patient empowerment.
Results
Between January and October 2021, 56 patients were included: 2 were rejected for presenting ventricular arrhythmias in the initial stress test and 4 due to technological barrier; 14 patients are currently performing the CRP. The preliminary results from the 36 patients who have completed the CRP show a significant increase in functional capacity, muscle strength, weekly training volume, adherence to Mediterranean diet, emotional state (anxiety) and quality of life (Picture 2). There have been no complications and patient’s adherence has been excellent for both exercise (85%) and educational (80%) sessions.
Conclusion
A holistic telematic CRP dedicated to patients after an ischemic cardiac event, including patients of both gender and of no age-limit, seems to be a feasible, safe and effective in improving maximal aerobic capacity, weekly training volume, muscle strength, quality of life, compliance with the Mediterranean diet and emotional state.
Collapse
|
12
|
Escudero-Acha P, Leizaola O, Lázaro N, Cordero M, Cossío AM, Ballesteros D, Recena P, Tizón AI, Palomo M, Del Campo MM, Freita S, Duerto J, Bilbao NM, Vidal B, González-Romero D, Diaz-Dominguez F, Revuelto J, Blasco ML, Domezain M, de la Concepción Pavía-Pesquera M, Rubio O, Estella A, Pobo A, Gomez-Acebo I, González-Castro A. ADENI-UCI study: Analysis of non-income decisions in ICU as a measure of limitation of life support treatments. Med Intensiva 2022; 46:192-200. [PMID: 35227639 DOI: 10.1016/j.medine.2022.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 10/23/2020] [Accepted: 11/07/2020] [Indexed: 06/14/2023]
Abstract
OBJECTIVE To analyze the variables associated with ICU refusal decisions as a life support treatment limitation measure. DESIGN Prospective, multicentrico. SCOPE 62 ICU from Spain between February 2018 and March 2019. PATIENTS Over 18 years of age who were denied entry into ICU as a life support treatment limitation measure. INTERVENTIONS None. MAIN INTEREST VARIABLES Patient comorities, functional situation as measured by the KNAUS and Karnosfky scale; predicted scales of Lee and Charlson; severity of the sick person measured by the APACHE II and SOFA scales, which justifies the decision-making, a person to whom the information is transmitted; date of discharge or in-hospital death, destination for hospital discharge. RESULTS A total of 2312 non-income decisions were recorded as an LTSV measure of which 2284 were analyzed. The main reason for consultation was respiratory failure (1080 [47.29%]). The poor estimated quality of life of the sick (1417 [62.04%]), the presence of a severe chronic disease (1367 [59.85%]) and the prior functional limitation of patients (1270 [55.60%]) were the main reasons for denying admission. The in-hospital mortality rate was 60.33%. The futility of treatment was found as a risk factor associated with mortality (OR: 3.23; IC95%: 2.62-3.99). CONCLUSIONS Decisions to limit ICU entry as an LTSV measure are based on the same reasons as decisions made within the ICU. The futility valued by the intensivist is adequately related to the final result of death.
Collapse
|
13
|
Droguerre M, Vidal B, Valdebenito M, Mouthon F, Zimmer L, Charvériat M. Impaired Local and Long-Range Brain Connectivity and Visual Response in a Genetic Rat Model of Hyperactivity Revealed by Functional Ultrasound. Front Neurosci 2022; 16:865140. [PMID: 35401075 PMCID: PMC8987929 DOI: 10.3389/fnins.2022.865140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Accepted: 02/21/2022] [Indexed: 11/13/2022] Open
Abstract
Attention-Deficit hyperactivity disorder (ADHD) is a central nervous system (CNS) disorder frequently associated with other psychiatric disorders. Pathophysiology processes at stake in ADHD are still under investigation and interestingly neuroimaging data points to modulated brain connectivity in patients. The genetic spontaneously hypertensive rat (SHR) model has been widely used to study pathophysiological underpinnings of ADHD and resting-state brain connectivity using functional magnetic resonance imaging. Here, functional ultrasound imaging, a new technique enabling fast measurement of cerebral blood volume (CBV), was used to further characterize resting-state functional connectivity – at both local and long-range – and visual response in SHR. We demonstrated that response to visual stimulation was increased in SHR in the visual cortex and the superior colliculus. They displayed altered long-range functional connectivity between spatially distinct regions. SHR also displayed modulated local connectivity, with strong increases of regional homogeneity in parts of the motor and visual cortex, along with decreases in the secondary cingulate cortex, the superior colliculus and the pretectal area. As CBV is intricately coupled to cerebral activity, these results suggest an abnormal neural activity in the SHR animal model, consistent with previous clinical studies and demonstrate the potential of functional ultrasound imaging as a translational tool in ADHD.
Collapse
|
14
|
Flamarique I, Vidal B, Plana MT, Andrés-Perpiñá S, Gárriz M, Sánchez P, Pajuelo C, Mont L, Castro-Fornieles J. Long-term cardiac assessment in a sample of adolescent-onset anorexia nervosa. J Eat Disord 2022; 10:12. [PMID: 35101147 PMCID: PMC8802465 DOI: 10.1186/s40337-022-00533-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Accepted: 01/19/2022] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND High mortality rates have been reported in patients with anorexia nervosa, mainly due to cardiovascular alterations. The purpose of the present study was to assess cardiac structural and functional abnormalities some 20 years after initial treatment in a sample of adolescent-onset anorexia nervosa (A-AN) and to compare them with matched healthy controls (HC). METHODS A sample of 29 women diagnosed and treated for AN during adolescence (A-AN) were assessed more than 20 years later. A complete cardiac evaluation was carried out including an electrocardiogram (ECG) and a standard 2D echocardiography. Thirty matched HC were also assessed. RESULTS In the A-AN group, four subjects had a body mass index lower than 18.5 and met full DSM 5 criteria for AN at follow-up (Low-Weight group). They were compared with the rest of the sample (n = 25) who had normalized their weight (Normal-Weight group), though some still showed some eating disorder symptoms. Both groups were compared with the HC group. Subjects in the Low-Weight group presented statistically significant decreases in the left ventricular end-diastolic and left atrium dimensions and left ventricular mass in comparison with the Normal-Weight group and the HC. No other differences in cardiac parameters were found between groups. CONCLUSIONS Echocardiographic and ECG parameters of adults who had presented A-AN twenty years earlier and currently maintained normal weight were similar to those of HC who had never been treated or diagnosed with AN. Adult subjects with A-AN who still had low weight in the long term present certain cardiac abnormalities similar to those seen in short-lasting disease. More studies are needed to confirm these results in a larger sample.
Collapse
|
15
|
Vidal B, Levigoureux E, Chaib S, Bouillot C, Billard T, Newman-Tancredi A, Zimmer L. Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson’s Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. JOURNAL OF PARKINSONS DISEASE 2021; 11:1257-1269. [DOI: 10.3233/jpd-212580] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Background: The gold-standard treatment for Parkinson’s disease is L-DOPA, which in the long term often leads to levodopa-induced dyskinesia. Serotonergic neurons are partially responsible for this, by converting L-DOPA into dopamine leading to its uncontrolled release as a “false neurotransmitter”. The stimulation of 5-HT1A receptors can reduce involuntary movements but this mechanism is poorly understood. Objective: This study aimed to investigate the functionality of 5-HT1A receptors using positron emission tomography in hemiparkinsonian rats with or without dyskinesia induced by 3-weeks daily treatment with L-DOPA. Imaging sessions were performed “off” L-DOPA. Methods: Each rat underwent a positron emission tomography scan with [18F]F13640, a 5-HT1AR agonist which labels receptors in a high affinity state for agonists, or with [18F]MPPF, a 5-HT1AR antagonist which labels all the receptors. Results: There were decreases of [18F]MPPF binding in hemiparkinsonian rats in cortical areas. In dyskinetic animals, changes were slighter but also found in other regions. In hemiparkinsonian rats, [18F]F13640 uptake was decreased bilaterally in the globus pallidus and thalamus. On the non-lesioned side, binding was increased in the insula, the hippocampus and the amygdala. In dyskinetic animals, [18F]F13640 binding was strongly increased in cortical and limbic areas, especially in the non-lesioned side. Conclusion: These data suggest that agonist and antagonist 5-HT1A receptor-binding sites are differently modified in Parkinson’s disease and levodopa-induced dyskinesia. In particular, these observations suggest a substantial involvement of the functional state of 5-HT1AR in levodopa-induced dyskinesia and emphasize the need to characterize this state using agonist radiotracers in physiological and pathological conditions.
Collapse
|
16
|
Vidal B, Droguerre M, Venet L, Valdebenito M, Mouthon F, Zimmer L, Charvériat M. Inter-subject registration and application of the SIGMA rat brain atlas for regional labeling in functional ultrasound imaging. J Neurosci Methods 2021; 355:109139. [PMID: 33741345 DOI: 10.1016/j.jneumeth.2021.109139] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Revised: 03/09/2021] [Accepted: 03/12/2021] [Indexed: 11/16/2022]
Abstract
BACKGROUND Recent advances using functional ultrasound (fUS) imaging have opened new avenues to evaluate brain activity through the regional monitoring of cerebral blood volume (CBV) dynamics. In particular, this technology paves the way for understanding physiological or pathological cerebral processes or exploring the pharmacological profiles of new drugs targeting brain disorders. One of the main difficulties of this technology is the lack of standardized and validated tools, in particular relevant brain atlases, to help improving the accuracy, automation and reproducibility of fUS data analysis. NEW METHOD Here, we demonstrate the possibility to use the MRI-validated SIGMA brain atlas in rat to perform fast and precise analysis of CBV changes in numerous functionally relevant regions of interest using fUS imaging. We applied this atlas to a dataset obtained in anesthetized rats evaluating the cerebral effects of atomoxetine, a norepinephrine reuptake inhibitor currently marketed in attention-deficit/hyperactivity-disorder. RESULTS This approach enabled to show the subregional effects of atomoxetine in the rat with very few inter-individual differences in some areas, such as the dentate gyrus. CONCLUSIONS We show the feasibility of inter-individual registration of 2D pharmaco-fUS data and subsequent detailed analysis using the SIGMA atlas.
Collapse
|
17
|
Colom M, Vidal B, Fieux S, Redoute J, Costes N, Lavenne F, Mérida I, Irace Z, Iecker T, Bouillot C, Billard T, Newman-Tancredi A, Zimmer L. [ 18F]F13640, a 5-HT 1A Receptor Radiopharmaceutical Sensitive to Brain Serotonin Fluctuations. Front Neurosci 2021; 15:622423. [PMID: 33762906 PMCID: PMC7982540 DOI: 10.3389/fnins.2021.622423] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Accepted: 02/17/2021] [Indexed: 12/30/2022] Open
Abstract
Introduction Serotonin is involved in a variety of physiological functions and brain disorders. In this context, efforts have been made to investigate the in vivo fluctuations of this neurotransmitter using positron emission tomography (PET) imaging paradigms. Since serotonin is a full agonist, it binds preferentially to G-protein coupled receptors. In contrast, antagonist PET ligands additionally interact with uncoupled receptors. This could explain the lack of sensitivity to serotonin fluctuations of current 5-HT1A radiopharmaceuticals which are mainly antagonists and suggests that agonist radiotracers would be more appropriate to measure changes in neurotransmitter release. The present study evaluated the sensitivity to endogenous serotonin release of a recently developed, selective 5-HT1A receptor PET radiopharmaceutical, the agonist [18F]F13640 (a.k.a. befiradol or NLX-112). Materials and Methods Four cats each underwent three PET scans with [18F]F13640, i.e., a control PET scan of 90 min, a PET scan preceded 30 min before by an intravenous injection 1 mg/kg of d-fenfluramine, a serotonin releaser (blocking challenge), and a PET scan comprising the intravenous injection of 1 mg/kg of d-fenfluramine 30 min after the radiotracer injection (displacement challenge). Data were analyzed with regions of interest and voxel-based approaches. A lp-ntPET model approach was implemented to determine the dynamic of serotonin release during the challenge study. Results D-fenfluramine pretreatment elicited a massive inhibition of [18F]F13640 labeling in regions known to express 5-HT1A receptors, e.g., raphe nuclei, hippocampus, thalamus, anterior cingulate cortex, caudate putamen, occipital, frontal and parietal cortices, and gray matter of cerebellum. Administration of d-fenfluramine during PET acquisition indicates changes in occupancy from 10% (thalamus) to 31% (gray matter of cerebellum) even though the dissociation rate of [18F]F13640 over the 90 min acquisition time was modest. The lp-ntPET simulation succeeded in differentiating the control and challenge conditions. Conclusion The present findings demonstrate that labeling of 5-HT1A receptors with [18F]F13640 is sensitive to serotonin concentration fluctuations in vivo. Although the data underline the need to perform longer PET scan to ensure accurate measure of displacement, they support clinical development of [18F]F13640 as a tool to explore experimental paradigms involving physiological or pathological (neurological or neuropsychiatric pathologies) fluctuations of extracellular serotonin.
Collapse
|
18
|
Escudero-Acha P, Leizaola O, Lázaro N, Cordero M, Cossío AM, Ballesteros D, Recena P, Tizón AI, Palomo M, Del Campo MM, Freita S, Duerto J, Bilbao NM, Vidal B, González-Romero D, Diaz-Dominguez F, Revuelto J, Blasco ML, Domezain M, de la Concepción Pavía-Pesquera M, Rubio O, Estella A, Pobo A, Gomez-Acebo I, González-Castro A. ADENI-UCI Study: Analysis of non-income decisions in ICU as a measure of limitation of life support treatments. Med Intensiva 2020; 46:S0210-5691(20)30342-9. [PMID: 33386143 DOI: 10.1016/j.medin.2020.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 10/23/2020] [Accepted: 11/07/2020] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To analyze the variables associated with ICU refusal decisions as a life support treatment limitation measure. DESIGN Prospective, multicentrico SCOPE: 62 ICU from Spain between February 2018 and March 2019. PATIENTS Over 18 years of age who were denied entry into ICU as a life support treatment limitation measure. INTERVENTIONS None. MAIN INTEREST VARIABLES Patient comorities, functional situation as measured by the KNAUS and Karnosfky scale; predicted scales of Lee and Charlson; severity of the sick person measured by the APACHE II and SOFA scales, which justifies the decision-making, a person to whom the information is transmitted; date of discharge or in-hospital death, destination for hospital discharge. RESULTS A total of 2312 non-income decisions were recorded as an LTSV measure of which 2284 were analyzed. The main reason for consultation was respiratory failure (1080 [47.29%]). The poor estimated quality of life of the sick (1417 [62.04%]), the presence of a severe chronic disease (1367 [59.85%]) and the prior functional limitation of patients (1270 [55.60%]) were the main reasons for denying admission. The in-hospital mortality rate was 60.33%. The futility of treatment was found as a risk factor associated with mortality (OR: 3.23; IC95%: 2.62-3.99). CONCLUSIONS Decisions to limit ICU entry as an LTSV measure are based on the same reasons as decisions made within the ICU. The futility valued by the intensivist is adequately related to the final result of death.
Collapse
|
19
|
Loza A, del Nogal F, Macías D, León C, Socías L, Herrera L, Yuste L, Ferrero J, Vidal B, Sánchez J, Zabalegui A, Saavedra P, Lesmes A. Predictors of mortality and neurological function in ICU patients recovering from cardiac arrest: A Spanish nationwide prospective cohort study. Med Intensiva 2020; 44:463-474. [DOI: 10.1016/j.medin.2020.02.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 01/24/2020] [Accepted: 02/09/2020] [Indexed: 12/24/2022]
|
20
|
Abuli M, Sanz-De La Garza M, Vidal B, Doltra A, Sarquella Brugada G, Carvalho S, Santiago J, Rodas G, Guasch E, Sitges M. Aortic stiffness and distensibility in elite athletes: impact of discipline and gender. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Aortic remodeling in athletes is variable among sports disciplines with more ascending aorta (Asc Ao) dilatation in endurance (EAs) as compared to power athletes (PAs). Nevertheless, the impact of this differential remodeling on the Asc Ao functional properties is not well established. The aim of this study was to assess the distensibility and stiffness of the ascending aorta in endurance and power elite athletes in order to evaluate if this aortic remodeling implies functional changes.
Methods
119 elite athletes (61 EA and 58 PA, 49% female sex, mean age: 18.7±7.1 years) underwent standardized pre-participation screening with 12 lead ECG, transthoracic echocardiography and maximum stress test. Asc Ao diameter was measured from parasternal long axis views in 2D echocardiography. The aortic distensibility index (ADi) was calculated as 2 × (systolic Asc Ao diameter − diastolic Asc Ao diameter) / (diastolic Asc Ao diameter) × (pulse pressure) (cm–2 dyn–1 10–6). Aortic stiffness (AS) index was defined as Ln (systolic blood pressure/diastolic blood pressure) / (systolic Asc Ao diameter − diastolic Asc Ao diameter)/diastolic proximal Asc Ao diameter.
Results
Globally, EA presented larger AscAO, both in absolute and indexed values, than PA (28±3.0 vs 26±3.0cm, p<0.001 and 16.4±1.5 vs 15.7±1.9cm, p<0.05, while were no differences in AS or ADi) (Figure 1A). Nevertheless, ADi in male EAs was higher than in male PAs (ADi: 4.3±1.7 vs 3.2±1.3 cm2/dyn/10–6, p<0.05) and AS was lower (AS: 4.7±1.7 vs 6.3±3.8, P<0.005) (Figure 1B and 1C). Female athletes presented higher ADi (ADi: 4.7±1.9 vs 4.0±1.6 cm, p<0.05) and a trend towards lower AS (4.8±2.9 vs 5.1±2.6, p: 0.4) than male athletes. There were no differences in AS or ADi between female EAs and PAs.
Conclusion
Male EAs showed an increased aortic distensibility with lower stiffness as compared to that observed in male PAs. This difference was not observed in female EAs and PAs, potentially due to better baseline distensibility with less room for improvement with endurance training.
Funding Acknowledgement
Type of funding source: None
Collapse
|
21
|
Vidal B, Droguerre M, Venet L, Zimmer L, Valdebenito M, Mouthon F, Charvériat M. Functional ultrasound imaging to study brain dynamics: Application of pharmaco-fUS to atomoxetine. Neuropharmacology 2020; 179:108273. [DOI: 10.1016/j.neuropharm.2020.108273] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 07/29/2020] [Accepted: 08/10/2020] [Indexed: 12/20/2022]
|
22
|
Toulemonde P, Vidal B, Mizrahi A, Nguyen Van J, Lourtet J, El Helali N, Perniceni L, Le Monnier A, Couzigou C. Dynamique de l’excrétion virale chez les patients infectés par le SARS-CoV-2. Med Mal Infect 2020. [PMCID: PMC7441967 DOI: 10.1016/j.medmal.2020.06.441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Introduction La durée de contagiosité d’un patient infecté par le SARS-CoV-2 n’est à ce jour pas encore clairement définie. Dans l’attente de nouvelles données, des recommandations sur les critères de levées d’isolement (précautions gouttelettes et contact), ont été émises par le Haut Conseil de santé publique. Ces recommandations se basent sur des critères cliniques et temporels et recommandent une durée totale d’isolement d’au moins 14 jours après le début des symptômes en population générale et d’au moins 24 jours chez les patients immunodéprimés. D’autres recommandations internationales (notamment celles de l’eCDC et des Chinoises) associent aux critères de levée d’isolement, une à deux PCR de contrôle sur écouvillons nasopharyngés. Notre établissement centralise depuis le début de l’épidémie les prélèvements pour recherche de SARS-CoV-2 par RT-PCR sur écouvillons nasopharyngés pour 7 établissements de santé. L’objectif de notre étude a été d’évaluer la proportion de patients gardant une PCR positive à SARS-CoV-2 au-delà de 24 jours après la première PCR positive. Matériels et méthodes Étude rétrospective incluant l’ensemble des patients ayant eu un dépistage par PCR nasopharyngée (3 mars–10 juin 2020) au sein des 7 établissements. Les données analysées ont inclus l’âge des patients, le délai de réalisation (en jours) entre 2 PCR, le service clinique. Résultats À la date du 10 juin, 3603 dépistages (dont 37 non-rendus pour problèmes techniques) ont été réalisés chez 3032 patients ; parmi ces patients, 348 ont eu plusieurs dépistages : 278 ont été dépistés deux fois, 47 trois fois, et 23 quatre fois ou plus. La répartition des patients gardant une PCR positive au moins 24 jours après la première était la suivante : – 20 patients ont eu un dépistage de contrôle entre 24 et 29 jours après le premier dépistage : 1 patient était encore positif à j27 (5 %) ; – 42 patients ont eu un dépistage de contrôle entre 30 et 41 jours : 8 étaient encore positifs (19 %) ; – 34 patients ont eu un dépistage de contrôle après 42 jours : 3 étaient encore positifs (9 %). Les 12 patients gardant une PCR positive au moins 24 jours après la première, avaient été hospitalisés, avaient une moyenne d’âge de 66 ans et 7 d’entre eux avaient un cancer sous-jacent ou avaient nécessité une prise en charge en réanimation. Conclusion Plus de 10 % des patients dépistés au moins 24 jours après le diagnostic microbiologique gardait une PCR nasopharyngée positive. Même si l’excrétion d’ARN viral n’équivaut pas directement à l’infectiosité, au vu des inconnues encore importantes sur le SARS-CoV-2, la levée précoce de l’isolement doit être réfléchie au cas par cas, en particulier pour les formes graves et les patients immunodéprimés.
Collapse
|
23
|
Vidal B, Droguerre M, Valdebenito M, Zimmer L, Hamon M, Mouthon F, Charvériat M. Pharmaco-fUS for Characterizing Drugs for Alzheimer's Disease - The Case of THN201, a Drug Combination of Donepezil Plus Mefloquine. Front Neurosci 2020; 14:835. [PMID: 32903470 PMCID: PMC7437134 DOI: 10.3389/fnins.2020.00835] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 07/17/2020] [Indexed: 01/29/2023] Open
Abstract
Donepezil is a potent acetylcholinesterase inhibitor, largely used worldwide to alleviate cognitive symptoms in Alzheimer’s disease (AD). Beyond the widely described neuronal impact of donepezil, it was recently shown that targeting connexins, the proteins involved in astrocyte network organization, potentiates donepezil efficacy profile using behavioral tests in AD rodent models. We herein present data demonstrating the potential of functional ultrasound imaging to monitor cerebral activity changes after pharmacological challenge in mice. As an example, we showed that although administration of donepezil or mefloquine alone at low dose had only very limited effects on the signal compared to the baseline, their combination produced marked hemodynamic effects in the hippocampus, in line with previously published behavioral data demonstrating a synergic interaction between both drugs. Thus, the present study provides new perspectives, (i) through the use of pharmaco-fUS, a new non-clinical imaging modality, to move forward drug discovery in AD and (ii) by the profiling of two drug treatments on brain dynamics, one used in AD: donepezil, and the other in development: donepezil combined with mefloquine (THN201) as a modulator of astrocyte network.
Collapse
|
24
|
Irace Z, Mérida I, Redouté J, Fonteneau C, Suaud-Chagny MF, Brunelin J, Vidal B, Zimmer L, Reilhac A, Costes N. Bayesian Estimation of the ntPET Model in Single-Scan Competition PET Studies. Front Physiol 2020; 11:498. [PMID: 32508679 PMCID: PMC7248280 DOI: 10.3389/fphys.2020.00498] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Accepted: 04/23/2020] [Indexed: 11/13/2022] Open
Abstract
This paper proposes an innovative method, named b-ntPET, for solving a competition model in PET. The model is built upon the state-of-the-art method called lp-ntPET. It consists in identifying the parameters of the PET kinetic model relative to a reference region that rule the steady state exchanges, together with the identification of four additional parameters defining a displacement curve caused by an endogenous neurotransmitter discharge, or by a competing injected drug targeting the same receptors as the PET tracer. The resolution process of lp-ntPET is however suboptimal due to the use of discretized basis functions, and is very sensitive to noise, limiting its sensitivity and accuracy. Contrary to the original method, our proposed resolution approach first estimates the probability distribution of the unknown parameters using Markov-Chain Monte-Carlo sampling, distributions from which the estimates are then inferred. In addition, and for increased robustness, the noise level is jointly estimated with the parameters of the model. Finally, the resolution is formulated in a Bayesian framework, allowing the introduction of prior knowledge on the parameters to guide the estimation process toward realistic solutions. The performance of our method was first assessed and compared head-to-head with the reference method lp-ntPET using well-controlled realistic simulated data. The results showed that the b-ntPET method is substantially more robust to noise and much more sensitive and accurate than lp-ntPET. We then applied the model to experimental animal data acquired in pharmacological challenge studies and human data with endogenous releases induced by transcranial direct current stimulation. In the drug challenge experiment on cats using [18F]MPPF, a serotoninergic 1A antagonist radioligand, b-ntPET measured a dose response associated with the amount of the challenged injected concurrent 5-HT1A agonist, where lp-ntPET failed. In human [11C]raclopride experiment, contrary to lp-ntPET, b-ntPET successfully detected significant endogenous dopamine releases induced by the stimulation. In conclusion, our results showed that the proposed method b-ntPET has similar performance to lp-ntPET for detecting displacements, but with higher resistance to noise and better robustness to various experimental contexts. These improvements lead to the possibility of detecting and characterizing dynamic drug occupancy from a single PET scan more efficiently.
Collapse
|
25
|
Emery S, Fieux S, Vidal B, Courault P, Bouvard S, Tourvieille C, Iecker T, Billard T, Zimmer L, Lancelot S. Preclinical validation of [ 18F]2FNQ1P as a specific PET radiotracer of 5-HT 6 receptors in rat, pig, non-human primate and human brain tissue. Nucl Med Biol 2020; 82-83:57-63. [PMID: 32006785 DOI: 10.1016/j.nucmedbio.2020.01.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 01/17/2020] [Accepted: 01/21/2020] [Indexed: 12/20/2022]
Abstract
INTRODUCTION The aim of this study was to perform in-vitro and in-vivo radiopharmacological characterizations of [18F]2FNQ1P, a new PET radiotracer of 5-HT6 receptors, in rat, pig, non-human primate and human tissues. The 5-HT6 receptor is one of the more recently identified serotonin receptors in central nervous system and, because of its role in memory and cognitive processes, is considered as a promising therapeutic target. METHODS In-vitro autoradiography and saturation binding assays were performed in postmortem brain tissues from rat, pig, non-human primate and human caudate nucleus, completed by serum stability assessment in all species and cerebral radiometabolite and biodistribution studies in rat. RESULTS In all species, autoradiography data revealed high binding levels of [18F]2FNQ1P in cerebral regions with high 5-HT6 receptor density. Binding was blocked by addition of SB258585 as a specific antagonist. Binding assays provided KD and Bmax values of respectively 1.34 nM and 0.03 pmol·mg-1 in rat, 0.60 nM and 0.04 pmol·mg-1 in pig, 1.38 nM and 0.07 pmol·mg-1 in non-human primate, and 1.39 nM and 0.15 pmol·mg-1 in human caudate nucleus. In rat brain, the proportion of unmetabolized [18F]2FNQ1P was >99% 5 min after iv injection and 89% at 40 min. The biodistribution studies found maximal radioactivity in lungs and kidneys (3.5 ± 1.2% ID/g and 2.0 ± 0.7% ID/g, respectively, 15 min post-injection). CONCLUSION These radiopharmacological data confirm that [18F]2FNQ1P is a specific radiotracer for molecular imaging of 5-HT6 receptors and suggest that it could be used as a radiopharmaceutical in humans.
Collapse
|